Recent News

Bladder Drug Manufacturers Face Lawsuits Over Retinal Damage Linked to Elmiron

On Wednesday, August 12th, women in two separate complaints filed suit against units of Johnson & Johnson, Bayer and Teva Pharmaceuticals USA Inc. after they developed eye damage after taking bladder medication Elmiron. Here, the pharmaceutical liability attorneys at Peter Angelos P.C. discuss the latest updates in Elmiron litigation and what it means for patients…

Read More...

Elmiron Update: Warnings Changed to Include Risk of Eye Damage

On June 16th, 2020,  the Food and Drug Administration (FDA) announced labeling changes to Elmiron, a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Here, the pharmaceutical liability attorneys at Peter Angelos P.C. discuss the potential dangers to consumers taking Elmiron, and how to seek legal representation…

Read More...

Elmiron Linked to Vision Loss

Elmiron is a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Recently, Elmiron has been linked to the increased risk of pigmentary maculopathy and other forms of vision loss and damage. The pharmaceutical liability attorneys at Peter Angelos P.C. Law are actively investigating cases regarding the use…

Read More...

FDA Requests Removal of Zantac From the Market Immediately

On April 1st, the Food and Drug Administration (FDA) announced its request for all prescription and over-the-counter ranitidine drugs to be removed from the market immediately. This decision was made based on an ongoing investigation of possible carcinogenic effects of the contaminant N-nitrosodimethylamine, or NDMA. Here, the pharmaceutical liability attorneys at Peter Angelos, P.C. discuss…

Read More...

Zantac Manufacturer Recalls Medication Due to Confirmed Contamination

Sandoz Inc. has voluntarily recalled the generic version of common medication Zantac after the medication was confirmed to be contaminated with a human carcinogen. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the updates to the ongoing Zantac claims.  Global health regulators recently raised concerns about the possibility that the…

Read More...

Carcinogen Found in Stomach Drug Leads to Halt in Distribution

Global health regulators have raised the alarm about the possibility that the widely used drug, Zantac, could be tainted with the same cancer-causing agent found in Valsartan earlier this year. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos detail the preliminary results of the FDA and EU probes. Officials are Investigating…

Read More...

Updates on Link Between Flesh-Eating Genital Infection and Diabetes Drug SGLT2 Inhibitors

A recent study investigated a potential link between a Type-2 diabetes drug and a severe and potentially fatal necrotizing fasciitis called Fournier gangrene. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the recent study and how SGLT2 inhibitors may potentially be linked to the development of Fournier gangrene. The First…

Read More...

FDA Includes Black Box Warning on Gout Medicine Uloric

As of February 2019, the U.S. Food and Drug Administration has stated that there is a higher risk of death associated with gout medicine Uloric (febuxostat) compared to other gout medicines. The FDA has now included a Black Box Warning for Uloric as a result of the recent findings. Here, the pharmaceutical liability attorneys at…

Read More...

Updates on Risks Surrounding Proton Pump Inhibitors (PPIs)

Proton pump inhibitors (PPIs) decrease the production of stomach acid that is responsible for the development of ulcers in the stomach, duodenum and esophagus. However, this grouping of drugs is linked to a variety of risks and side effects, and there is a growing list of lawsuits that have been filed in response to these…

Read More...

Zostavax 2019 Litigation Updates

Zostavax, a vaccine administered to protect against herpes zoster, otherwise known as shingles, is now being contested in approximately 550 cases in multidistrict litigation (MDL). Here, the Baltimore pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss updates in Zostavax litigation for 2019. Zostavax was Intended to Weaken the Shingles Virus When Zostavax…

Read More...